We are live on ! Find out more
BLFS icon

BioLife Solutions

140 hedge funds and large institutions have $743M invested in BioLife Solutions in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 48 increasing their positions, 54 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

611% more call options, than puts

Call options by funds: $3.75M | Put options by funds: $528K

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

24% more capital invested

Capital invested by funds: $602M → $743M (+$142M)

1.34% more ownership

Funds ownership: 100.19%101.53% (+1.3%)

8% less funds holding

Funds holding: 153140 (-13)

11% less repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 54

42% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 24

Holders
140
Holders Change
-13
Holders Change %
-8.5%
% of All Funds
2.04%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
14
Increased
48
Reduced
54
Closed
24
Calls
$3.75M
Puts
$528K
Net Calls
+$3.22M
Net Calls Change
+$2.9M
Name Holding Trade Value Shares
Change
Change in
Stake
RIM
26
Ranger Investment Management
Texas
$5.91M +$292K +22,906 +7%
JP Morgan Chase
27
JP Morgan Chase
New York
$5.77M -$249K -19,541 -5%
Bank of America
28
Bank of America
North Carolina
$5.05M -$691K -54,133 -15%
PCM
29
Peregrine Capital Management
Minnesota
$4.77M -$646K -50,663 -15%
Fidelity Investments
30
Fidelity Investments
Massachusetts
$4.71M -$17.1K -1,343 -0.5%
Charles Schwab
31
Charles Schwab
California
$4.63M +$39.9K +3,126 +1%
RC
32
Roubaix Capital
Colorado
$4.56M +$1.7M +133,439 +91%
GA
33
Gagnon Advisors
New York
$4.46M -$1.1M -86,541 -24%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$4.4M -$59.8K -4,690 -2%
UIC
35
Uniplan Investment Counsel
Wisconsin
$4.13M -$175K -13,712 -5%
PAMP
36
Polar Asset Management Partners
Ontario, Canada
$3.93M +$3.08M +241,600 New
PCP
37
Pacific Capital Partners
$3.25M -$957K -75,000 -27%
Principal Financial Group
38
Principal Financial Group
Iowa
$3.04M -$40.7K -3,194 -2%
Russell Investments Group
39
Russell Investments Group
United Kingdom
$2.97M -$25.4K -1,993 -1%
ZDA
40
Zweig-DiMenna Associates
New York
$2.67M -$214K -16,770 -9%
BFS
41
Bard Financial Services
Connecticut
$2.17M
HNB
42
Huntington National Bank
Ohio
$2M
Tudor Investment Corp
43
Tudor Investment Corp
Connecticut
$1.81M +$466K +36,537 +49%
MAG
44
Millrace Asset Group
Pennsylvania
$1.72M +$724K +56,726 +116%
Legal & General Group
45
Legal & General Group
United Kingdom
$1.66M +$4.85K +380 +0.4%
Macquarie Group
46
Macquarie Group
Australia
$1.56M +$179K +13,995 +17%
Victory Capital Management
47
Victory Capital Management
Texas
$1.56M -$275K -21,589 -18%
Barclays
48
Barclays
United Kingdom
$1.55M +$486K +38,120 +67%
B
49
Barings
North Carolina
$1.48M
RG
50
Rathbones Group
United Kingdom
$1.43M

BLFS Hedge Fund Activity: Q4 2023 in Review

140 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q4 2023, worth a combined $743M — up 24% from $602M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of BLFS and 14 opened new positions — a net loss of 10 holders — while 54 trimmed existing stakes and 48 added.

The largest buyer was Goldman Sachs, adding an estimated $28M. The largest seller was Park West Asset Management, exiting entirely with an estimated $27.8M sold.

  • 140 institutional investors held BioLife Solutions (BLFS) as of Q4 2023, down from 153 in Q3 2023.
  • Funds reported $743M of BioLife Solutions stock for Q4 2023, up 24% quarter-over-quarter.
  • 14 funds opened new BioLife Solutions positions in Q4 2023 and 24 closed out, a net change of -10 holders.
  • The largest BioLife Solutions buyer in Q4 2023 was Goldman Sachs, an estimated $28M added.
  • The largest BioLife Solutions seller in Q4 2023 was Park West Asset Management, an estimated $27.8M sold.

Based on aggregated 13F filings for Q4 2023.